Patient empowerment and optimal glycemic control

Current Medical Research and Opinion

Volumn 28, Issue 6, 2012, Pages 979-989

  White, Russell D ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes education; Empower; Glycemic control; Insulin; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIG INSULIN; RECOMBINANT HUMAN INSULIN;

ALGORITHM; BODY WEIGHT; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERANCE; EMPOWERMENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH EDUCATION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATIENT EDUCATION; PEER REVIEW; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERSONALIZED MEDICINE; POSTPRANDIAL STATE; PROBLEM SOLVING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF CARE; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT-CENTERED CARE; POWER (PSYCHOLOGY); SELF CARE;

EID: 84862576192     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.677417     Document Type: Review

References (62)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. Funnell MM, Anderson RM. Empowerment and self-management of diabetes. Clin Diabetes 2004;22:123-7.
3. Funnell MM, Tang TS, Anderson RM. From DSME to DMS: developing empowerment-based diabetes self-management support. Diabetes Spectr 2007;20:221-6.
4. Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007;21:220-6.
5. Funnell MM, Kruger DF, Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ 2004;30:274-80.
6. Selam JL, Koenen C, Weng W, et al. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11-20.
7. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
8. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-8.
9. TM 303 study. Diabetes Obes Metab 2007;9:902-13.
10. Raslova K, Tamer SC, Clauson P, et al. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Invest 2007;27:279-85.
11. Davies M, Sinnassamy P, Storms F, et al. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract 2008; 79:368-75.
12. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16.
13. Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25:542-8.
14. Selam JL, Meneghini LF. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. Adv Ther 2009;26:194-207.
15. Fonseca V, Davidson J, Home P, et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin 2010;26:1621-8.
16. Meyer C, Boron A, Plummer E, et al. Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study. Diabetes Care 2010; 33:2496-501.
17. Ratner R, Wynne A, Nakhle S, et al. Influence of preprandial versus postprandial insulin glulisine on weight and glycemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obes Metab 2011;13:1142-8.
18. Qaseem A, Vijan S, Snow V, et al. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007;147:417-22.
19. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35(Suppl 1):S11-63.
20. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17(Suppl 2):1-53.
21. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
22. Atar D, Birkeland KI, Uhlig T. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann Rheum Dis 2010;69:629-30.
23. ATLAS Study Group. Titration of insulin glargine in patients with type 2 diabetes mellitus in Asia: physician-versus patient-led? Rationale of the Asian Treat to Target Lantus Study (ATLAS). Diabetes Technol Ther 2011;13:67-72.
24. Harris SB, Kapor J, Lank CN, et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010;56:e418-24.
25. Serrano-Gil M, Jacob S. Engaging and empowering patients to manage their type 2 diabetes, part I: a knowledge, attitude, and practice gap? Adv Ther 2010;27:321-33
26. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 2010;33:733-5.
27. Eliasson B, Cederholm J, Nilsson P, et al. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 2005;22:1420-6.
28. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
29. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359:1618-20.
30. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
31. Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894-9.
32. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3.
33. ACCORD Study Group, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28.
34. Weder AB. Discord from ACCORD? Curr Hypertens Rep 2011;13:1-4
35. Davila EP, Florez H, Trepka MJ, et al. Strict glycemic control and mortality risk among US adults with type 2 diabetes. J Diabetes Complications 2011; 25:289-91.
36. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-804.
37. Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:E924-30.
38. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004; 70:489-500.
39. Tibaldi J. Preserving insulin secretion in type 2 diabetes mellitus. Expert Rev Endocrinol Metab 2008;3:147-59.
40. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7.
41. Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-4.
42. Herbert RJ, Gagnon AJ, Rennick JE, et al. A systematic review of questionnaires measuring health-related empowerment. Res Theory Nurs Pract 2009;23:107-32.
43. Musacchio N, Lovagnini SA, Giancaterini A, et al. Impact of a chronic care model based on patient empowerment on the management of type 2 diabetes: effects of the SINERGIA programme. Diabet Med 2011;28:724-30.
44. Asimakopoulou K, Gilbert D, Newton P, et al. Back to basics: re-examining the role of patient empowerment in diabetes. Patient Educ Couns 2011;May 2 [Epub ahead of print]
45. Tang TS, Funnell MM, Brown MB, et al. Self-management support in 'real-world' settings: an empowerment-based intervention. Patient Educ Couns 2010;79:178-84.
46. Lowe JM, Mensch M, McElduff P, et al. Does an advanced insulin education programme improve outcomes and health service use for people with type 2 diabetes? A 5-year follow-up of the Newcastle Empowerment course. Diabet Med 2009;26:1277-81.
47. Mayberry R, Josiah-Willock R, Boone L, et al. A high level of patient activation is observed but unrelated to glycemic control among adults with type 2 diabetes. Diabetes Spectr 2010;23:171-6.
48. Philis-Tsimikas A, Walker C, Rivard L, et al. Improvement in diabetes care of underinsured patients enrolled in project dulce: a community-based, culturally appropriate, nurse case management and peer education diabetes care model. Diabetes Care 2004;27:110-15.
49. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83.
50. Allen J. Comparison of insulins. Pharmacist's Letter/Prescriber's Letter 2006;22:220910.
51. Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications 2007; 21: 196-204.
52. Davies MJ, Derezinski T, Pedersen CB, et al. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypogly-cemia. Diabetes Technol Ther 2008;10:273-7.
53. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglita-zone in type 2 diabetes. Diabetes Care 2002;25:1691-8.
54. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002; 4: 673-82.
55. Heinemann L, Sinha K, Weyer C, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999; 16: 332-8.
56. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabet Rev 1997;5:177-269.
57. Holman RR. Assessing the potential for a-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998;40(Suppl):S21-5.
58. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
59. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hypergly-cemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
60. Monnier L, Colette C. Target for glycemic control: concentrating on glucose. Diabetes Care 2009;32(Suppl 2):S199-204.
61. Thurman JE. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States. Endocr Pract 2007;13:672-8.
62. Asakura T, Seino H, Kageyama M, et al. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin 2008;24:1429-34.